

## NeoDynamics to present NeoNavia® at the British Society of Breast Radiology meeting in Belfast on 5-7 November 2023

**NeoDynamics will participate in the British Society of Breast Radiology (BSBR) meeting in Belfast on 5-7 November 2023, which is one of the busiest events in the UK breast radiology calendar with representation from most major hospitals in the UK.**

NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD. ST), will present the company's innovative biopsy system, NeoNavia® at the BSBR event where the system will be available for practitioners to try. Initial feedback on the system is very promising with UK radiologists reporting improved control due to the pulse technology. Another reported major benefit is the time saved as it is possible to switch between different needle types within 30 seconds.

"It's great to finally have the complete system with all three needle options available to demonstrate. We have already secured some initial orders and the BSBR provides the platform to start growing the business in 2024" says Ian Galloway, Country Manager, UK & Ireland.

**For further information, please contact:**

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail [anna.eriksrud@neodynamics.com](mailto:anna.eriksrud@neodynamics.com)

Ian Galloway, Country Manager UK & Ireland, phone +447885 369 062 or e-mail [ian.galloway@neodynamics.com](mailto:ian.galloway@neodynamics.com)

**About NeoNavia**

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

**About NeoDynamics**

NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company's first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic's shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company's Certified Adviser is Redeye AB.

## **About Karolinska Institute**

The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.

## **Attachments**

[NeoDynamics to present NeoNavia® at the British Society of Breast Radiology meeting in Belfast on 5-7 November 2023](#)